Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hendriks

Showing results (311-320 of 344) with videos related to

Pageof 35
Sort By:
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2022
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trialFenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, et al.
Lung Cancer (Amsterdam, Netherlands)|September 4, 2025
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastasesJarno W J Huijs, Anna M Sadowska, Juliette H R J Degens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
Nature Communications|June 14, 2022
Automated detection and segmentation of non-small cell lung cancer computed tomography imagesSergey P Primakov, Abdalla Ibrahim, Janita E van Timmeren, et al.
Brain Research. Molecular Brain Research|May 29, 1998
Amyloid-beta-protein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer diseaseA Tamaoka, P E Fraser, K Ishii, et al.
Frontiers in Oncology|May 22, 2023
Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancerAnita J W M Brouns, Lizza E L Hendriks, Iris J Robbesom-van den Berge, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic TherapiesJonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, et al.
Pageof 35

Showing results (311-320 of 344) with videos related to

Sort By:
Pageof 35
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2022
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trialFenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, et al.
Lung Cancer (Amsterdam, Netherlands)|September 4, 2025
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastasesJarno W J Huijs, Anna M Sadowska, Juliette H R J Degens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
Nature Communications|June 14, 2022
Automated detection and segmentation of non-small cell lung cancer computed tomography imagesSergey P Primakov, Abdalla Ibrahim, Janita E van Timmeren, et al.
Brain Research. Molecular Brain Research|May 29, 1998
Amyloid-beta-protein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer diseaseA Tamaoka, P E Fraser, K Ishii, et al.
Frontiers in Oncology|May 22, 2023
Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancerAnita J W M Brouns, Lizza E L Hendriks, Iris J Robbesom-van den Berge, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic TherapiesJonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, et al.
Pageof 35